Guselkumab
Guselkumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Crohn's Disease。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
8 项
已进入 III/IV 期
23 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Janssen Research & Development, LLC
- Weill Medical College of Cornell University
- Janssen-Cilag A.G., Switzerland
- Sixth Affiliated Hospital, Sun Yat-sen University
- Janssen-Cilag G.m.b.H
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Leiden University Medical Center
- Centre Hospitalier Universitaire de Nice
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、瑞士、中国、德国、奥地利、比利时、加拿大、Czechia、丹麦、法国、Hungary、意大利
正在招募患者的 Guselkumab 研究
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
III 期招募中美国NCT06274554A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab
不适用招募中瑞士NCT07532213Real-World Study of IL-23 Inhibitors in Active Crohn's Disease
不适用招募中中国NCT07545317A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany
不适用招募中德国NCT07102368A Prospective Observational Study on the Efficacy and Safety of Guselkumab in the Treatment of Crohn's Disease Patients Previously Treated With Ustekinumab
不适用招募中中国NCT07487480A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
III 期招募中美国奥地利比利时加拿大NCT07499232SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
不适用招募中荷兰NCT07021495Real-Life Evaluation of Guselkumab Dosing Interval Adjustments
不适用招募中法国NCT07430319Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
II 期招募中美国NCT07138898Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
不适用招募中英国NCT07166315A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
III 期招募中美国Argentina澳大利亚比利时NCT06663332Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
不适用招募中加拿大NCT07245394A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
III 期招募中美国澳大利亚奥地利比利时NCT05923073A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice
不适用招募中HungaryNCT07746583Proactive TDM Versus Standard Use of Biologics in Psoriasis
IV 期招募中比利时NCT06398106A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi Arabia
不适用招募中Saudi ArabiaNCT07541261Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis
不适用招募中中国NCT07726888A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
III 期招募中美国Argentina澳大利亚奥地利NCT07577856A Study of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis
不适用招募中奥地利NCT07606339Efficacy of Guselkumab in Treating Hailey Hailey Disease
II 期招募中美国NCT06651489Potential Role of Guselkumab in Modulating PAIN Perception and Related Gene Pathways: a Proof-of-concept Study.
IV 期招募中意大利NCT06974474Immune Spatial Features of Guselkumab Cutaneous Response
IV 期招募中美国NCT05858632Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
不适用招募中美国NCT06586281PsoBest - The German Psoriasis Registry
不适用招募中德国NCT01848028
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。